Reason for removal from study
No. of patients . | Reason, patient no. . |
|---|---|
| 4 | Progressed (never responded): 8, 22, 29, 37* |
| 6 | Progressed (after minor response): 22, 29, 29, 36, 72, 74, 213 |
| 5 | Progressed (after major response): 72, 90, 162, 300†, 330 |
| 2 | Toxicity (never responded): 15, 15 |
| 3 | Removed for BMT after response: 62 (minor), 74 (major), 99 (major) before transplantation |
No. of patients . | Reason, patient no. . |
|---|---|
| 4 | Progressed (never responded): 8, 22, 29, 37* |
| 6 | Progressed (after minor response): 22, 29, 29, 36, 72, 74, 213 |
| 5 | Progressed (after major response): 72, 90, 162, 300†, 330 |
| 2 | Toxicity (never responded): 15, 15 |
| 3 | Removed for BMT after response: 62 (minor), 74 (major), 99 (major) before transplantation |
Minor response indicates a 50% reduction in peripheral blasts; major response, a significant clinical benefit defined as a 2-log reduction in peripheral blasts for at least 4 weeks.
Numbers refer to the day a given patient stopped drug.
This patient did not receive PKC412 between day 165 and day 270.